SEC Form 4 · accession 0001012975-17-000720
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Enright
Officer — President and CEO · Director
Period of report
Sep 22, 2017
Accepted (ET)
Sep 26, 2017 · 6:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (option to buy)F1 | $2.48 | Sep 22, 2017 | A | 125,000 | A | Mar 31, 2019 | Sep 22, 2027 | Common Stock, par value $0.0001 | 125,000 | 125,000 | D |
Explanation of responses
- F1The option becomes exercisable, if at all, on March 31, 2019, in three equal one-third increments if the average daily closing price of Altimmune, Inc.'s common stock on Nasdaq for 10 consecutive trading days between September 22, 2017 and December 31, 2018 is at or above one of three specified thresholds, respectively.